Baker Bros. Advisors LP Akari Therapeutics PLC Transaction History

Baker Bros. Advisors LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$1.82 - $2.56 $106,961 - $150,451	-58,770 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$1.77 - $2.28 $497,481 - $640,823	-281,063 Reduced 82.71%	58,770 $115,000
Q1 2018 May 15, 2018	SELL	$1.77 - $4.39 $632,010 - $1.57 Million	-357,068 Reduced 51.24%	339,833 $618,000
Q4 2017 Feb 14, 2018	BUY	$4.08 - $7.4 $816,000 - $1.48 Million	200,000 Added 40.25%	696,901 $3.02 Million
Q3 2017 Nov 14, 2017	BUY	$3.42 - $8.74 $1.7 Million - $4.34 Million	496,901	496,901 $3.05 Million

Ticker AKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,349,200
Market Cap $68.8M
Description
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.